Fontrexed 500mg powder

Ferron Par Pharmaceuticals

Ingredients in every vial

Pemetrexed disodium hemipentahydrate 500 mg

Each package contains

1 vial of 500 mg

Other details

Dosage form:Powder for injection
Flavour: None

W.H.O. classification

ATC Level 1: L - Antineoplastic and immunomodulating agents
ATC Level 2: L01 - Antineoplastic Agents
ATC Level 3: L01B - Antimetabolites

Warnings

Pregnancy

NOT SAFEThis item is not safe for use during pregnancy.

Lactation

NOT SAFEThis item is not safe for use during lactation.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution.

Available in

Indonesia

Dosage information

18 TO 65 YEARS OLD
Pemetrexed must only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy.
Pemetrexed in combination with cisplatin
The recommended dose of pemetrexed is 500 mg/m2 of body surface area (BSA), administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m2 BSA infused over 2 hours approximately 30 minutes after completion of the pemetrexed infusion on the first day of each 21-day cycle. Patients must receive adequate antiemetic treatment and appropriate hydration prior to and/or after receiving cisplatin.
Pemetrexed as a single agent
In patients treated for non-small cell lung cancer after prior chemotherapy, the recommended dose of pemetrexed is 500 mg/m2 BSA administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Premedication regimen
To reduce the incidence and severity of skin reactions, a corticosteroid should be given the day prior to, on the day of, and the day after pemetrexed administration. The corticosteroid should be equivalent to 4 mg of dexamethasone administered orally twice a day.

Pemetrexed must only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy.

Method of administration
Pemetrexed should be administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.

65 YEARS OLD AND ABOVE
There has been no indication that patients 65 years of age or older are at increased risk of adverse events compared to patients younger than 65 years old. No dose reductions other than those recommended for all patients are necessary.

Pemetrexed must only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy.

Method of administration
Pemetrexed should be administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.

OTHER DETAILS
RENAL IMPAIRMENT (standard Cockcroft and Gault formula or glomerular filtration rate measured Tc99m-DTPA serum clearance method)
Pemetrexed is primarily eliminated unchanged by renal excretion. Patients with creatinine clearance of ≥45 ml/minute required no dose adjustments other than those recommended for all patients. There are insufficient data on the use of pemetrexed in patients with creatinine clearance below 45 ml/minute; therefore, the use of pemetrexed is not recommended.

HEPATIC IMPAIRMENT
No relationships between AST (SGOT), ALT (SGPT), or total bilirubin and pemetrexed pharmacokinetics were identified. However, patients with hepatic impairment, such as bilirubin >1.5-times the upper limit of normal and/or aminotransferase >3.0-times the upper limit of normal (hepatic metastases absent) or >5.0-times the upper limit of normal (hepatic metastases present), have not been specifically studied.

Indication

Malignant pleural mesothelioma
Pemetrexed in combination with cisplatin is indicated for the treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma.
Non-small cell lung cancer
Pemetrexed in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
Pemetrexed is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. First-line treatment should be a platinum-based with other cytotoxics chemotherapy.
Pemetrexed is indicated as a single-agent for the treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy (as second line).Pemetrexed is not indicated for treatment of patients with squamous cell non-small cell lung cancer.

Disclaimer

The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.